Literature DB >> 2684520

Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Research Group for Clinical Assessment of rhEPO.

M Suzuki1, Y Hirasawa, K Hirashima, M Arakawa, M Odaka, Y Ogura, Y Yoshikawa, T Sanaka, A Shinoda, H Morii.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2684520     DOI： 10.1159/000417894

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  3 in total

Review 1.  Erythropoietin: physiology and molecular mechanisms.

Authors:  Robert N Foley
Journal:  Heart Fail Rev       Date:  2008-01-31       Impact factor: 4.214

Review 2.  Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

3.  The effect of erythropoietin on the cellular defence mechanism of red blood cells in children with chronic renal failure.

Authors:  S Túri; I Németh; I Varga; T Bodrogi; B Matkovics
Journal:  Pediatr Nephrol       Date:  1992-11       Impact factor: 3.714
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.